There's more inventory in general. There is still more supply than there is demand for online advertising.

All of our labeling and all of our advertising is developed in compliance with [Food and Drug Administration] regulations.

We will ensure that our advertising clearly sets out the relevant terms of the financing options.

Investors tend to get nervous around DOJ issues. Absolutely, it will help alleviate their fears.

There are some risks and challenges. As they expand internationally, their costs are going to go up. So we'll still see that top-line growth, but we'll see some pinch there on the costs and the operating margins.

We believe this position will ultimately bode well with its users and will not have a significant impact on current traffic and consequent advertising revenues. We recommend investors take advantage of any declines in the stock price today as an opportunity to buy.